Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced today that investigators enrolled the first patient in a study of its EsoGuard. Investigators at the Louis Stokes Cleveland Department of Veterans Affairs Medical Center enrolled the patient in a U.S. Department of Defense-funded study of the EsoGuard esophageal DNA test for at-risk patients with gastroesophageal reflux disease (GERD). Lucid Diagnostics […]
Lucid Diagnostics
Pavmed acquires CapNostics and its esophageal cell collection device
Pavmed (NSDQ:PAVM) announced today that it has agreed to buy CapNostics. The company entered into a definitive membership interest purchase agreement with Martin Von Dyck, the sole member and owner of North Carolina–based CapNostics, according to a news release. CapNostics manufactures the FDA-cleared and CE-marked EsophaCap non-endoscopic esophageal cell collection device used in pre-commercial clinical […]
Pavmed subsidiary Lucid Diagnostics files registration statement for IPO
Pavmed (NSDQ:PAVM) subsidiary Lucid Diagnostics announced that Lucid publicly filed a registration statement related to a proposed initial public offering (IPO). The number of shares of common stock and the price range for the offering have not yet been determined, according to a news release. Lucid Diagnostics intends to list its common stock on the Nasdaq market […]
Lucid Diagnostics gains CE mark for esophageal device
Lucid Diagnostics has received the CE mark for its EsoCheck esophageal cell collection device, its parent company announced today. EsoCheck is an FDA-cleared, swallowable balloon capsule catheter that enables a clinician to sample surface cells from the esophagus in a less than five-minute, non-invasive office procedure. Lucid touts EsoCheck as the only such device capable of […]
PavMed to spin off subsidiary Lucid Diagnostics
Pavmed (NSDQ:PAVM) announced today that its majority-owned subsidiary Lucid Diagnostics will spin off into a separate public company. In a news release, Pavmed said Lucid Diagnostics intends to spin off if favorable market conditions continue to hold, whether it be through an initial public offering (IPO) or a business combination with a healthcare special purpose acquisition corporation. […]
Pavmed’s Lucid Diagnostics enters clinical trial with U of Penn
Pavmed (NSDQ:PAVM) announced today that its majority-owned subsidiary Lucid Diagnostics entered into a clinical trial research agreement with the University of Pennsylvania to observe its EsoCheck esophageal cell collection device. EsoCheck with “collect & protect technology” is designed to offer a less invasive, more efficient and cost-effective alternative to endoscopic biopsies when managing patients with eosinophilic […]